idpickering wrote:Sotrovimab retains its activity vs Omicron variant
Preclinical studies demonstrate sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant
· New preclinical findings generated through in vitro testing of sotrovimab against the complete pseudo-virus, updated to bioRxiv
· Data build on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
· Sotrovimab is authorised and available for the treatment of early COVID-19 in the US and multiple countries around the world
https://www.investegate.co.uk/glaxosmit ... 07288046U/
Worth reading down to the end to see its limitations. I can't help wondering how often it will actually be used, in the UK at any rate, since my impression is that most people don't contact their GPs but go straight to hospital if they have severe symptoms and otherwise self-medicate.
"Limitations of Authorized Use
Sotrovimab is not authorized for use in patients:
· who are hospitalized due to COVID-19, OR
· who require oxygen therapy due to COVID-19, OR
· who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)
Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation."
There is also a list of contraindications and adverse events.